Publications

ABPPC has written a number of published articles on the subject of healthcare pricing and reimbursement.

Two of our published journal articles are shown below, including the abstracts along with a link to the publishers to obtain the full text. Below these are the details of and a link to an article written by Adam Barak for the monthly UK pharmaceutical/biotechnology newspaper Pharmafocus.

Pricing policies to handle patent loss or expiry

Abstract
Generics provide improved access to drugs for developed and developing world markets and offer payers and governments the opportunity to reduce the costs of their healthcare provision. Their main threat is the dramatic reduction in revenues for the original manufacturer. This paper looks at the matter from the point of view of pharmaceutical companies and outlines some of the ways in which pricing can be used to counter this threat and maximise revenues when patent protection is lost.

Published in International Journal of Medical Marketing
June 2003, Volume 3, Number 3, pp245-249

Pharmaceutical Pricing: Overview of the Impact of genericisation

Abstract
Patent expiry signals a fundamental shift in the way in which drugs are marketed and purchased. The entry of generic competitors requires a variety of different healthcare stakeholders to implement an alternative set of objectives and approaches in order to take advantage of the new opportunities which genericisation brings about. This paper concentrates on two perspectives, that of the original brand manufacturer and the payer. It examines through the use of international examples, how approaches to pricing change pre- and post-patent expiry in view of the altered objectives and regulatory framework. It is demonstrated that manufacturer and payer alike have a number of alternative pricing approaches which could be implemented, each having a different set of aims and consequences.

Published in Journal of Generic Medicines
October 2003, Volume 1, Issue 1, pp21-30

UK PPRS Overhaul

Following the 20/2/07 Office of Fair Trading (OFT) report into the future of the PPRS, and the Department of Health’s enthusiastic reception of its recommendation to introduce value based pricing into the UK, ABPPC is inputting into the decision process and providing guidance to its clients on the implications of the new system which is being developed to determine pricing and reimbursement of healthcare technologies in the UK.

Our initial views on the OFT Report were published in the Pharmafocus newspaper for March 2007 (Volume 9, Issue 3).

This link takes you to the transcript.